LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Search

Codexis Inc

Fechado

SetorSaúde

2.4 -0.41

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.4

Máximo

2.42

Indicadores-chave

By Trading Economics

Rendimento

-18M

-8.7M

Vendas

-24M

15M

EPS

-0.1

Margem de lucro

-57.083

Funcionários

146

EBITDA

-23M

-5.8M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+187.5% upside

Dividendos

By Acuity

Próximos Ganhos

12 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

8.6M

237M

Abertura anterior

2.81

Fecho anterior

2.4

Sentimento de Notícias

By Acuity

23%

77%

48 / 342 Ranking em Healthcare

Codexis Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Sobre Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat